Search clinical trials for: ARN-509

Total 8581 results

Aragon Pharmaceuticals, Inc.

Active, not recruiting

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

Prostate Cancer

United States
Aragon Pharmaceuticals, Inc.

Completed

14C-ARN-509 Microtracer Label AME and Absolute BA Study

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study of Apalutamide Administered Orally as Whole Tablets and as a Mixture in Applesauce in Healthy Participants

Healthy

Belgium
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy

Prostate Adenocarcinoma | Stage IIB Prostate Cancer AJCC v8

United States
Institut Paoli-Calmettes
Janssen-Cilag Ltd.

Unknown

Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer (PC-ARN)

Low Risk Prostate Cancer

France
Aragon Pharmaceuticals, Inc.

Completed

A Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 in Healthy Male Participants

Healthy

United States
University of Washington
National Cancer Institute (NCI); Janssen Scientific Affairs, LLC

Terminated

Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance

Prostate Adenocarcinoma

United States
Universitaire Ziekenhuizen KU Leuven

Active, not recruiting

Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy (ARNEO)

Prostate Cancer | Neoadjuvant Therapy | Prostatectomy | Androgen Antagonists

Belgium
National Cancer Institute (NCI)

Recruiting

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

Prostate Adenocarcinoma | Localized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8

United States
National Cancer Institute (NCI)

Not yet recruiting

Study to Determine Possible Effects of Apalutamide on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer

Non-Muscle Invasive Bladder Urothelial Carcinoma | Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma

United States
University of California, San Francisco
Janssen Pharmaceuticals

Active, not recruiting

Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer (PILLAR)

Castration-Resistant Prostate Carcinoma | PSA Progression | Stage IV Prostate Adenocarcinoma AJCC v7 | Castration Levels of Testosterone

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER (BALANCE)

PSA Progression | Stage III Prostate Adenocarcinoma | Stage IV Prostate Adenocarcinoma

United States, Canada
Aragon Pharmaceuticals, Inc.

Completed

Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants

Healthy

United States
Laboratoires NEGMA

Unknown

Study to Evaluate the Digestive Tolerability of ART44 Versus ART®50 in Patients With Osteoarthritis of the Knee

Knee Osteoarthritis
Aardvark Therapeutics, Inc.
Center for Psychiatry And Behavioral Medicine Inc.

Recruiting

A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder

Autism Spectrum Disorder

United States
Brigham and Women's Hospital
Harvard Medical School (HMS and HSDM); Weill Medical College of Cornell University and other collaborators

Unknown

Same-Day HIV Testing and Treatment Initiation to Improve Retention in Care

HIV

Haiti
Aragon Pharmaceuticals, Inc.

Active, not recruiting

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC (TITAN)

Prostate Cancer

United States, France, Poland, Ukraine, United Kingdom, China, Spain, Argentina, Israel, Mexico, Romania, Turkey, Korea, Republic of, Japan, Sweden, Canada, Russian Federation, Brazil, Germany, Hungary, Czechia, Australia
Janssen Research & Development, LLC

Active, not recruiting

A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

Prostatic Neoplasms

China
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer

Prostate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer... and other conditions

United States
Case Comprehensive Cancer Center

Completed

Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer

Prostate Cancer

United States
The University of Texas Health Science Center,...
Janssen Scientific Affairs, LLC

Withdrawn

Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer

Prostate Cancer

United States
Makerere University
Centre For International Health

Completed

SURVIVAL PLUSS: Increasing Capacity for Mama-baby Survival in Post-conflict Uganda and South Sudan

Preterm Birth | Neonatal Death | Low Birthweight | Neonatal Hypoglycemia

Uganda
GlaxoSmithKline

Completed

Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 in Healthy Participants Who Smoke Cigarettes

Asthma

United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects

Healthy

United States
Memorial Sloan Kettering Cancer Center
University of Michigan; Weill Medical College of Cornell University; Janssen...

Active, not recruiting

AASUR in High Risk Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center

Recruiting

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk

BRCA1 Mutation | BRCA2 Mutation | APC Gene Mutation | MLH1 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | PTEN Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | BARD1 Gene Mutation | MSH2 Gene Mutation | MSH6 Gene Mutation | PMS2 Gene Mutation | POLD1 Gene... and other conditions

United States
Carl Zeiss Meditec AG

Terminated

Clinical Safety and Efficacy of CT ASPHINA 509 Lenses (UVEA509)

Cataract

Germany
Sangamo Therapeutics

Completed

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Diabetic Polyneuropathy

United States, Mexico
Sangamo Therapeutics

Completed

Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Diabetic Polyneuropathy

United States
Hookipa Biotech GmbH

Recruiting

Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART

Human Immunodeficiency Virus (HIV) Infection

United States
Sangamo Therapeutics

Completed

Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS) (ALS)

Amyotrophic Lateral Sclerosis

United States
PENTA Foundation
Karolinska Institutet; Centre Hospitalier Universitaire Saint Pierre; Centro... and other collaborators

Active, not recruiting

European Pregnancy and Paediatric Infections Cohort Collaboration: Paediatric Protocol (EPPICC)

HIV Infections | Covid19 | Hepatitis C | Tuberculosis Infection
Instituto do Cancer do Estado de São Paulo
Janssen, LP

Completed

Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer

Prostate Cancer

Brazil
University of California, Los Angeles

Completed

Clinical Evaluation of Morcher Artificial Iris Diaphragms

Aniridia | Iris; Deformity

United States
Vertex Pharmaceuticals Incorporated

Completed

A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Poland, Belgium, Romania, Serbia, United States, Puerto Rico, Germany, Hungary, Russian Federation, Croatia
Vertex Pharmaceuticals Incorporated

Completed

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Rheumatoid Arthritis

United States, Denmark, Estonia, Lithuania, Netherlands, South Africa
University of North Carolina, Chapel Hill
National Institute on Drug Abuse (NIDA); National Institute on Alcohol Abuse... and other collaborators

Completed

Immunologic Memory (Supp. of ATN 024)

HIV Infections

United States
Arrien Pharmaceuticals
Worldwide Clinical Trials

Completed

A Phase 1 Study of ARN-6039 (ARN-6039)

Multiple Sclerosis
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy (CLMF237A1303)

Diabetes Mellitus, Type 2

Japan
Sangamo Therapeutics
Juvenile Diabetes Research Foundation

Completed

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Diabetic Polyneuropathy

United States, Mexico
Instituto Valenciano de Infertilidad, IVI VALENCIA

Withdrawn

Closed Vitrification of Oocytes

Infertility

Spain
VA Office of Research and Development

Completed

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

Newly Diagnosed Oligometastatic Prostate Cancer

United States
Anglia Ruskin University

Completed

Blue Light Emergency Services Wellbeing Feasibility Study

Wellbeing

United Kingdom
PurGenesis Technologies Inc.

Completed

Safety, Tolerability, Efficacy Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis

Left-Sided Ulcerative Colitis | Proctosigmoiditis

Germany
University of Plymouth
Carl Zeiss Meditec AG; University Hospital Plymouth NHS Trust; Glasgow Caledonian... and other collaborators

Recruiting

Vision and Balance Changes After Bilateral Implantation of Toric IOLs

Cataract Bilateral | Astigmatism Bilateral

United Kingdom
University of Portsmouth

Unknown

Float First: An Index of Floating: Factors Affecting Floating in Different Populations

Anthropometry | Lung Function | Floating Technique

United Kingdom
Pr. Nicolas GIRERD

Completed

- 4th Visit at 17 Years of Cohort STANISLAS - Stanislas Ancillary Study ESCIF (STANISLASV4)

Cardiovascular Diseases

France
Prof JMA Lange
European and Developing Countries Clinical Trials Partnership (EDCTP)

Terminated

Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment (PrOMPT)

HIV Infection | Tuberculosis

Gabon, Mozambique, Uganda
Sidney Kimmel Comprehensive Cancer Center at Johns...
Patient-Centered Outcomes Research Institute

Completed

Simplifying Survivorship Care Planning (SSCP)

Cancer

United States
Vertex Pharmaceuticals Incorporated

Completed

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Rheumatoid Arthritis

United States, Argentina, Bulgaria, Czech Republic, Estonia, Germany, Hungary, Mexico, Poland, Romania, Russian Federation, Serbia, Slovakia, Ukraine

Search clinical trials for: ARN-509

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations